A single center experience of concomitant administration of sofosbuvir/velpatasvir and amiodarone after heart and lung transplantation
The advent of direct-acting antiviral agents (DAA) allows for the utilization of hepatitis C (HCV) viremic donors to uninfected recipients. Sofosbuvir/velpatasvir (SOF/VEL) is a pangenotypic DAA without clinically significant interactions with immunosuppressants, but its concomitant use with amiodar...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-08-01
|
| Series: | JHLT Open |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2950133425000746 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849770458771095552 |
|---|---|
| author | Ryan M. Rivosecchi Pablo G. Sanchez Lauren M. Sacha Edward T. Horn Mary Keebler Fernanda P. Silveira |
| author_facet | Ryan M. Rivosecchi Pablo G. Sanchez Lauren M. Sacha Edward T. Horn Mary Keebler Fernanda P. Silveira |
| author_sort | Ryan M. Rivosecchi |
| collection | DOAJ |
| description | The advent of direct-acting antiviral agents (DAA) allows for the utilization of hepatitis C (HCV) viremic donors to uninfected recipients. Sofosbuvir/velpatasvir (SOF/VEL) is a pangenotypic DAA without clinically significant interactions with immunosuppressants, but its concomitant use with amiodarone may cause serious bradycardia. In an open-label study of 20 heart and lung transplant recipients of organs from HCV viremic donors, who received SOF/VEL for 12 weeks starting on post-operative day one, the concomitant use of amiodarone and SOF/VEL resulted in bradycardic episodes and commonly occurred in the presence of beta-blocking medications. Episodes of bradycardia were transient, resolved with intervention, and did not require the discontinuation of SOF/VEL. In patients requiring the combination of SOF/VEL and amiodarone, consideration of therapeutic options is warranted prior to the addition of other bradycardia-inducing medications. |
| format | Article |
| id | doaj-art-d21c074e78fa485a9116ade5ac384c85 |
| institution | DOAJ |
| issn | 2950-1334 |
| language | English |
| publishDate | 2025-08-01 |
| publisher | Elsevier |
| record_format | Article |
| series | JHLT Open |
| spelling | doaj-art-d21c074e78fa485a9116ade5ac384c852025-08-20T03:02:59ZengElsevierJHLT Open2950-13342025-08-01910027910.1016/j.jhlto.2025.100279A single center experience of concomitant administration of sofosbuvir/velpatasvir and amiodarone after heart and lung transplantationRyan M. Rivosecchi0Pablo G. Sanchez1Lauren M. Sacha2Edward T. Horn3Mary Keebler4Fernanda P. Silveira5Department of Pharmacy, UPMC Presbyterian, 200 Lothrop St., Pittsburgh, PA 15213Department of Cardiothoracic Surgery, UPMC Presbyterian, 200 Lothrop St., Pittsburgh, PA 15213Department of Pharmacy, UPMC Presbyterian, 200 Lothrop St., Pittsburgh, PA 15213Department of Pharmacy, UPMC Presbyterian, 200 Lothrop St., Pittsburgh, PA 15213; Department of Pharmacy and Therapeutics, University of Pittsburgh School of Pharmacy, 550 Scaife Hall, 3550 Terrace Street, Pittsburgh, PA 15213Department of Medicine, Division of Cardiology, University of Pittsburgh, 200 Lothrop St C-700, Pittsburgh, PA 15213Department of Medicine, Division of Infectious Diseases, University of Pittsburgh, 3601 Fifth Avenue Suite 5B, Pittsburgh, PA 15213; Corresponding author: Fernanda P. Silveira, Department of Medicine, Division of Infectious Diseases, University of Pittsburgh, Pittsburgh, PA 15213.The advent of direct-acting antiviral agents (DAA) allows for the utilization of hepatitis C (HCV) viremic donors to uninfected recipients. Sofosbuvir/velpatasvir (SOF/VEL) is a pangenotypic DAA without clinically significant interactions with immunosuppressants, but its concomitant use with amiodarone may cause serious bradycardia. In an open-label study of 20 heart and lung transplant recipients of organs from HCV viremic donors, who received SOF/VEL for 12 weeks starting on post-operative day one, the concomitant use of amiodarone and SOF/VEL resulted in bradycardic episodes and commonly occurred in the presence of beta-blocking medications. Episodes of bradycardia were transient, resolved with intervention, and did not require the discontinuation of SOF/VEL. In patients requiring the combination of SOF/VEL and amiodarone, consideration of therapeutic options is warranted prior to the addition of other bradycardia-inducing medications.http://www.sciencedirect.com/science/article/pii/S2950133425000746Hepatitis CAmiodaroneBradycardiaHeart transplantLung transplant |
| spellingShingle | Ryan M. Rivosecchi Pablo G. Sanchez Lauren M. Sacha Edward T. Horn Mary Keebler Fernanda P. Silveira A single center experience of concomitant administration of sofosbuvir/velpatasvir and amiodarone after heart and lung transplantation JHLT Open Hepatitis C Amiodarone Bradycardia Heart transplant Lung transplant |
| title | A single center experience of concomitant administration of sofosbuvir/velpatasvir and amiodarone after heart and lung transplantation |
| title_full | A single center experience of concomitant administration of sofosbuvir/velpatasvir and amiodarone after heart and lung transplantation |
| title_fullStr | A single center experience of concomitant administration of sofosbuvir/velpatasvir and amiodarone after heart and lung transplantation |
| title_full_unstemmed | A single center experience of concomitant administration of sofosbuvir/velpatasvir and amiodarone after heart and lung transplantation |
| title_short | A single center experience of concomitant administration of sofosbuvir/velpatasvir and amiodarone after heart and lung transplantation |
| title_sort | single center experience of concomitant administration of sofosbuvir velpatasvir and amiodarone after heart and lung transplantation |
| topic | Hepatitis C Amiodarone Bradycardia Heart transplant Lung transplant |
| url | http://www.sciencedirect.com/science/article/pii/S2950133425000746 |
| work_keys_str_mv | AT ryanmrivosecchi asinglecenterexperienceofconcomitantadministrationofsofosbuvirvelpatasvirandamiodaroneafterheartandlungtransplantation AT pablogsanchez asinglecenterexperienceofconcomitantadministrationofsofosbuvirvelpatasvirandamiodaroneafterheartandlungtransplantation AT laurenmsacha asinglecenterexperienceofconcomitantadministrationofsofosbuvirvelpatasvirandamiodaroneafterheartandlungtransplantation AT edwardthorn asinglecenterexperienceofconcomitantadministrationofsofosbuvirvelpatasvirandamiodaroneafterheartandlungtransplantation AT marykeebler asinglecenterexperienceofconcomitantadministrationofsofosbuvirvelpatasvirandamiodaroneafterheartandlungtransplantation AT fernandapsilveira asinglecenterexperienceofconcomitantadministrationofsofosbuvirvelpatasvirandamiodaroneafterheartandlungtransplantation AT ryanmrivosecchi singlecenterexperienceofconcomitantadministrationofsofosbuvirvelpatasvirandamiodaroneafterheartandlungtransplantation AT pablogsanchez singlecenterexperienceofconcomitantadministrationofsofosbuvirvelpatasvirandamiodaroneafterheartandlungtransplantation AT laurenmsacha singlecenterexperienceofconcomitantadministrationofsofosbuvirvelpatasvirandamiodaroneafterheartandlungtransplantation AT edwardthorn singlecenterexperienceofconcomitantadministrationofsofosbuvirvelpatasvirandamiodaroneafterheartandlungtransplantation AT marykeebler singlecenterexperienceofconcomitantadministrationofsofosbuvirvelpatasvirandamiodaroneafterheartandlungtransplantation AT fernandapsilveira singlecenterexperienceofconcomitantadministrationofsofosbuvirvelpatasvirandamiodaroneafterheartandlungtransplantation |